William Blair Comments on Harrow's Q2 Earnings (NASDAQ:HROW)

Harrow, Inc. (NASDAQ:HROW - Free Report) - William Blair issued their Q2 2025 earnings per share estimates for shares of Harrow in a research report issued on Tuesday, June 10th. William Blair analyst L. Hanbury-Brown forecasts that the company will post earnings per share of $0.00 for the quarter. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. William Blair also issued estimates for Harrow's Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.37 EPS, FY2025 earnings at $0.15 EPS and FY2026 earnings at $1.35 EPS.

Harrow (NASDAQ:HROW - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.40). The firm had revenue of $47.83 million during the quarter, compared to analyst estimates of $57.00 million. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%.

HROW has been the subject of a number of other research reports. BTIG Research started coverage on Harrow in a research note on Thursday. They set a "buy" rating and a $62.00 price target for the company. HC Wainwright boosted their target price on Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a research note on Monday, May 12th. Finally, B. Riley lowered their price target on shares of Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Harrow presently has an average rating of "Buy" and a consensus price target of $61.40.

Harrow Stock Down 2.7%

Shares of HROW traded down $0.85 during trading hours on Thursday, hitting $30.31. The stock had a trading volume of 291,166 shares, compared to its average volume of 502,508. The firm has a market capitalization of $1.11 billion, a P/E ratio of -32.24 and a beta of 0.40. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow has a 1-year low of $16.87 and a 1-year high of $59.23. The firm has a 50 day simple moving average of $26.16 and a 200-day simple moving average of $29.51.

Institutional Investors Weigh In On Harrow

A number of hedge funds and other institutional investors have recently bought and sold shares of HROW. GF Fund Management CO. LTD. purchased a new position in shares of Harrow during the 4th quarter valued at $25,000. Quarry LP purchased a new stake in Harrow during the first quarter valued at about $32,000. Tower Research Capital LLC TRC raised its stake in shares of Harrow by 769.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after acquiring an additional 1,462 shares during the last quarter. Aquatic Capital Management LLC bought a new position in shares of Harrow during the fourth quarter valued at about $78,000. Finally, State of Wyoming bought a new position in shares of Harrow during the first quarter valued at about $97,000. Institutional investors own 72.76% of the company's stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.